Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials - Concepedia

Concepedia

Publication | Open Access

Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

DOI Full Paper Access

51

Citations

20

References

2020

Year

Carine Beysen, Patricia Schroeder, Eric Wu, Julie Brevard, Maria Ribadeneira, Wei Lu, Kiran Dole, Terry O’Reilly, Linda Morrow, Marcus Hompesch,

Diabetes Obesity and Metabolism

Abstract

Inhibition of FASN with 3 mg FT-4101 safely reduces hepatic DNL and steatosis in NAFLD patients.

References

	Year	Citations

Page 1